Berkshire Hathaway’s Teva Pharmaceuticals TEVA Stock Holding History

Berkshire Hathaway’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-42,789,295	Closed	-$417M	–	46
2021 Q3	$417M	Hold	42,789,295	–	–	0.14%	30
2021 Q2	$424M	Hold	42,789,295	–	–	0.14%	32
2021 Q1	$494M	Hold	42,789,295	–	–	0.18%	32
2020 Q4	$413M	Hold	42,789,295	–	–	0.15%	35
2020 Q3	$386M	Hold	42,789,295	–	–	0.16%	33
2020 Q2	$528M	Hold	42,789,295	–	–	0.26%	26
2020 Q1	$384M	Sell	42,789,295 -460,000	-1%	-$4.71M	0.22%	31
2019 Q4	$424M	Hold	43,249,295	–	–	0.18%	39
2019 Q3	$298M	Hold	43,249,295	–	–	0.14%	40
2019 Q2	$399M	Hold	43,249,295	–	–	0.19%	39
2019 Q1	$678M	Hold	43,249,295	–	–	0.34%	31
2018 Q4	$667M	Hold	43,249,295	–	–	0.36%	31
2018 Q3	$932M	Hold	43,249,295	–	–	0.42%	27
2018 Q2	$1.05B	Buy	43,249,295 +2,709,585	+7%	+$55.3M	0.54%	23
2018 Q1	$693M	Buy	40,539,710 +21,663,989	+115%	+$423M	0.37%	30
2017 Q4	$358M	Buy	+18,875,721	New	+$284M	0.19%	35

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Berkshire Hathaway's TEVA Position: Q4 2021 in Review

Berkshire Hathaway sold out of Teva Pharmaceuticals (TEVA) in Q4 2021, closing a stake of 42,789,295 shares — an estimated $417M sold.

Berkshire Hathaway first reported a position in TEVA in Q4 2017 and held it in 16 quarters. The position peaked at $1.05B in Q2 2018. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.

Berkshire Hathaway reported no remaining Teva Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Berkshire Hathaway sold 42,789,295 Teva Pharmaceuticals shares in Q4 2021, an estimated $417M.
Berkshire Hathaway first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 16 quarters.
Berkshire Hathaway's Teva Pharmaceuticals position peaked at $1.05B in Q2 2018.
450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2021.

Based on Berkshire Hathaway's 13F filing for Q4 2021, filed 14 Feb 2022.